How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
Nuvation takes the battle to Nuvalent
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
